Skip to content
Clinical Trials – home

Bambino Gesu Childrens Hospital

Verifiedinfo

Italy Piazza Di Sant'onofrio 4, 00165 Rome, Italy

  • 5 trials recruiting
  • Migraine · Systemic lupus erythematosus · B-cell type acute leukaemia
  • Adults and children

About Specializations

Main research areas of the site

Respiratory Tract Diseases

The department is conducting studies on severe eosinophilic asthma in children, testing new biologic agents to lower attack frequency.

  • Asthma
  • Severe uncontrolled asthma
  • Pediatric severe asthma

Ongoing trials evaluate benralizumab and tezepelumab for safety and efficacy in reducing exacerbations and improving lung function.

Immune System Diseases

Research focuses on rare autoinflammatory diseases and broader autoimmune conditions, seeking targeted therapies that modulate immune pathways.

  • Autoinflammatory diseases (NLRC4‑GOF, XIAP deficiency, CDC42 mutation)
  • Immunoglobulin G4‑related disease
  • Generalized Myasthenia Gravis
  • Systemic Lupus Erythematosus

Trials assess agents such as MAS825, inebilizumab, and anifrolumab for disease control and safety in pediatric populations.

Digestive System Diseases

The site is evaluating novel biologics for chronic inflammatory bowel conditions, aiming to achieve durable remission in young patients.

  • Crohn's disease
  • Ulcerative colitis
  • Inflammatory Bowel Disease

Studies test mirikizumab, guselkumab, and long‑term vedolizumab therapy to improve mucosal healing and quality of life.

Hemic and Lymphatic Diseases

Investigations target bleeding disorders and pediatric blood cancers, exploring both replacement strategies and immune‑based treatments.

  • Hemophilia A and B
  • Philadelphia chromosome‑positive B‑ALL
  • Acute Myeloid Leukemia with NPM1 mutation
  • Hematopoietic stem cell transplantation in ALL

Trials include marstacimab for hemophilia, blinatumomab as post‑transplant maintenance, and protocols to refine transplant conditioning.

Musculoskeletal and Neurological Diseases

Pediatric rare‑disease programs evaluate disease‑modifying agents for muscle and nerve disorders, aiming to preserve function and delay progression.

  • Duchenne muscular dystrophy
  • CACNA1A‑related ataxia disorders
  • Metachromatic Leukodystrophy
  • Developmental and Epileptic Encephalopathies

Ongoing studies test givinostat, N‑Acetyl‑L‑Leucine, and gene‑replacement therapy HGT‑1110 for safety and functional improvement.

Hormonal and Congenital Disorders

The hospital investigates treatments for inherited and hormonal conditions that affect growth, kidney function, and metabolic balance.

  • Congenital adrenal hyperplasia
  • Alport syndrome
  • Chronic kidney disease

Clinical work includes evaluating atumelnant for adrenal disease control and BAY 3401016 to reduce albuminuria in Alport syndrome patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazza Di Sant'onofrio 400165 RomeItaly
Recruiting now
5 trials
Conditions studied
13
Partner status
Verified

More sites in RomeItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Videja B.V.
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.
Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:IRCCS Istituto Giannina Gaslini
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ciclosporin
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.